Skip to content
Markets News
Stocks1 min read

Liminatus Clears Nasdaq Bid-Price Rule After Reverse Split

Makkler Newsroom
September 29, 2026

Nasdaq closed its compliance matter after Liminatus shares stayed above $1 for 13 consecutive trading days following a 1-for-50 reverse split.

Liminatus Pharma said Nasdaq confirmed it had regained compliance with the exchange’s minimum bid-price rule. Nasdaq closed the matter after the company’s shares finished above $1 for 13 consecutive trading days.

Nasdaq notified Liminatus on Jan. 15, 2026, that its closing bid had been below $1 for 30 consecutive business days. That left the company out of compliance with the minimum bid-price requirement for the Nasdaq Global Market.

After an appeal and hearing, a Nasdaq panel transferred Liminatus to the Nasdaq Capital Market effective Aug. 4. It gave the company until Sept. 3 to meet that market’s bid-price requirement. Liminatus completed a 1-for-50 reverse stock split at the close of trading on Aug. 20.

In a Sept. 24 notice, Nasdaq said the closing bid was above $1 per share for 13 consecutive trading days, from Aug. 21 to Sept. 9. The company said Nasdaq’s determination restored its compliance.

Liminatus is a biotechnology company developing immuno-oncology and cell therapy candidates. Its programs include IBA101, an anti-CD47 antibody, and IBC101, a CAR-T candidate for B-cell malignancies.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.